A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Trial Profile

A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Brain metastases; Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms CheckMate204
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 06 Jun 2017 Results (n=75, data cut off November 2016) assessing efficacy and safety, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2017 Results from this trial published in a Bristol-Myers Squibb Media Release.
    • 04 Jun 2017 According to a Bristol-Myers Squibb media release, data from this trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top